Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vaxcyte, Inc.
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
March 04, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 15, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
February 01, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Announces Pricing of $750 Million Public Offering
January 30, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 30, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
January 29, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Appoints Whitney Jones as Chief People Officer
January 16, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
January 04, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
December 04, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Appoints Jacks Lee to Board of Directors
November 28, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
November 27, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
STRO
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
November 09, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
November 06, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte to Present at Upcoming Investor Conferences
October 31, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
October 16, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 19, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
July 11, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update
May 08, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte to Present at the BofA Securities 2023 Health Care Conference
May 03, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 21, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Announces Pricing of $500 Million Public Offering
April 19, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
April 17, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies
April 17, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies
April 16, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
March 30, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.